دورية أكاديمية
Effectiveness and Safety of Initiation and Titration of Insulin Glargine 300 U/mL in Insulin-Naive Patients with Type 2 Diabetes Mellitus Uncontrolled on Oral Antidiabetic Drug Treatment in Turkey: The EASE Study
| العنوان: | Effectiveness and Safety of Initiation and Titration of Insulin Glargine 300 U/mL in Insulin-Naive Patients with Type 2 Diabetes Mellitus Uncontrolled on Oral Antidiabetic Drug Treatment in Turkey: The EASE Study |
|---|---|
| المؤلفون: | Çetinarslan B., Çetinkalp Ş., Kaya A., Ersoy C., Kebapçı N., Çömlekçi A., Tütüncü N.B. |
| بيانات النشر: | AVES |
| سنة النشر: | 2024 |
| مصطلحات موضوعية: | Gla-300, HbA1c, hypoglycemia, insulin, insulin-naïve, OAD, type 2 diabetes mellitus, 2,4 thiazolidinedione derivative, alanine aminotransferase, alkaline phosphatase, alpha glucosidase inhibitor, aspartate aminotransferase, bilirubin, creatinine, dipeptidyl peptidase IV inhibitor, gamma glutamyltransferase, glucagon like peptide 1 receptor agonist, hemoglobin A1c, insulin derivative, insulin glargine, insulin injection pen, meglitinide, metformin, nicotine, oral antidiabetic agent, sodium glucose cotransporter 2 inhibitor, sulfonylurea, accuracy, adult, alcohol consumption |
| الوصف: | Objective: The aim of the study was to evaluate the effectiveness and safety of insulin glargine 300 U/ mL (Gla-300) in insulin-naive patients with type 2 diabetes mellitus (T2DM) inadequately controlled on oral antidiabetic drug (OADs) treatment in Turkey. Methods: One hundred eight patients from 20 centers enrolled in the study. Starting from baseline, Gla-300 was self-administered subcutaneously and once daily in the evening. The primary outcome was the mean change in glycated hemoglobin A1c (HbA1c) from baseline to week 24. Results: The mean (±SD) Hb1Ac level of 9.4% (±0.8) at baseline decreased to 7.5% (±0.9) at week 12 (P <.1) and to 7.3% (±0.9) at week 24 (P <.1). Although none of the patients were within the target Hb1Ac level of ?7% at baseline, the percentage of patients who achieved the target Hb1Ac level was 30.4% at week 12 and increased to 42.9% at week 24. Gla-300 treatment achieved the Hb1Ac target in 21 (19.4%) patients without experiencing a hypoglycemic event and in 27 (25.0%) patients who experienced at least one hypoglycemic event. For each self-monitoring blood glucose time point, significant improvements were observed as compared to baseline (P <.001). Statistically significant improvement (P <.001) was seen in the treatment satisfaction questionnaire – status version scores between baseline and week 24. Conclusion: This study indicated that Gla-300 is effective to provide a successful glycemic control with low risk of hypoglycemia added to OADs in insulin-naive patients with T2DM, and it has the potential to improve the quality of life of patients. © Author(s). ; Funding: The study was funded by Sanofi Türkiye. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 28226135 |
| العلاقة: | Endocrinology Research and Practice; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://doi.org/10.5152/erp.2024.23311Test; https://hdl.handle.net/20.500.12831/19866Test; 28; 11; 2-s2.0-85182491370 |
| DOI: | 10.5152/erp.2024.23311 |
| الإتاحة: | https://doi.org/10.5152/erp.2024.23311Test https://doi.org/20.500.12831/19866Test https://hdl.handle.net/20.500.12831/19866Test |
| حقوق: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.F9D93097 |
| قاعدة البيانات: | BASE |
| تدمد: | 28226135 |
|---|---|
| DOI: | 10.5152/erp.2024.23311 |